Document is current
Any future updates will be listed below
-
Authors
Quak, Elske https://orcid.org/0000-0003-0791-9899
Lasne-Cardon, Audrey
Cavarec, Marie
Jegoux, Franck
Guery, Clémence
Grellard, Jean-Michel
Thomas, Guy
Nadin, Lawrence
Clarisse, Bénédicte
Berchi, Celia
-
Funding
Funding for this research was provided by:
Fondation de l'Avenir pour la Recherche Médicale Appliquée (2018-AP-RM-18-030)
- License Information
-
More Information
Article History
Received: 6 August 2025
Accepted: 25 November 2025
First Online: 6 January 2026
Declarations
:
: The APACH2 trial was approved by the Local Medical Ethics Committee South-East II in July 2019 (Reference 2019–35, N° EudraCT: 2019–000274-36) and by the French Agency for Medical and Health products Safety (Reference: MEDAECNAT-2019–04-00001_2019-000274–36) in May 2019. The trial protocol was performed in accordance with the ethical standards of the Helsinki Declaration.
: All patients gave written informed consent before study entry and any study procedures.
: The authors declare that they have no conflict of interest in relation to this work.Dr Quak has received speaker and consultant honoraria from Adacap and Curium Pharma.
